Literature DB >> 17531208

Inactivation of the 5-HT(7) receptor partially blocks phencyclidine-induced disruption of prepulse inhibition.

Svetlana Semenova1, Mark A Geyer, J Gregor Sutcliffe, Athina Markou, Peter B Hedlund.   

Abstract

BACKGROUND: Studies have implicated the serotonin (5-HT)(7) receptor in physiological and pathophysiological phenomena, including thermoregulation, central control of micturition and locomotion, regulation of circadian rhythm, sleep, and depression. Further, several antidepressant and antipsychotic drugs have high affinity for the 5-HT(7) receptor.
METHODS: We examined the role of 5-HT(7) receptors in a rodent analogue of sensorimotor gating deficits in schizophrenia: phencyclidine (PCP)-induced disruption of prepulse inhibition (PPI) of acoustic startle. We used mice lacking the 5-HT(7) receptor due to a targeted inactivation of this receptor gene and the selective 5-HT(7) receptor antagonist SB-269970.
RESULTS: SB-269970 did not affect either baseline PPI or PCP-disrupted PPI. There was no difference between 5-HT(7)(+/+) and 5-HT(7)(-/-) mice in startle reactivity or PPI regardless of prepulse intensity (74-82 dB), interstimulus interval (25-500 msec), or pulse intensity (90-120 dB). Nevertheless, disruption of PPI produced by PCP (10 mg/kg) in wild-type mice was reduced in 5-HT(7)(-/-) mice, although it was not affected by the 5-HT(7) antagonist SB-269970. By contrast, the PPI-disruptive effects of apomorphine (5 mg/kg) and amphetamine (7.5 mg/kg) were comparable in both genotypes.
CONCLUSIONS: The results indicate a partial role for the 5-HT(7) receptor in the glutamatergic PPI model of sensorimotor gating deficits in schizophrenia that is sensitive to atypical antipsychotics and no involvement of this receptor in the dopaminergic PPI model that is sensitive to typical antipsychotics. Thus, the 5-HT(7)(-/-) mice may provide a useful tool to study the role of 5-HT(7) receptor in the action of atypical antipsychotic drugs and schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531208      PMCID: PMC2174622          DOI: 10.1016/j.biopsych.2006.12.011

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  30 in total

Review 1.  Functional, molecular and pharmacological advances in 5-HT7 receptor research.

Authors:  Peter B Hedlund; J Gregor Sutcliffe
Journal:  Trends Pharmacol Sci       Date:  2004-09       Impact factor: 14.819

Review 2.  Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia.

Authors:  N R Swerdlow; M A Geyer
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

3.  5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern.

Authors:  Peter B Hedlund; Salvador Huitron-Resendiz; Steven J Henriksen; J Gregor Sutcliffe
Journal:  Biol Psychiatry       Date:  2005-07-14       Impact factor: 13.382

4.  Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.

Authors:  Y Shen; F J Monsma; M A Metcalf; P A Jose; M W Hamblin; D R Sibley
Journal:  J Biol Chem       Date:  1993-08-25       Impact factor: 5.157

Review 5.  Neurobiological similarities in depression and drug dependence: a self-medication hypothesis.

Authors:  A Markou; T R Kosten; G F Koob
Journal:  Neuropsychopharmacology       Date:  1998-03       Impact factor: 7.853

Review 6.  Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients.

Authors:  N R Swerdlow; D L Braff; N Taaid; M A Geyer
Journal:  Arch Gen Psychiatry       Date:  1994-02

7.  Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response.

Authors:  V P Bakshi; N R Swerdlow; M A Geyer
Journal:  J Pharmacol Exp Ther       Date:  1994-11       Impact factor: 4.030

8.  Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression.

Authors:  M Guscott; L J Bristow; K Hadingham; T W Rosahl; M S Beer; J A Stanton; F Bromidge; A P Owens; I Huscroft; J Myers; N M Rupniak; S Patel; P J Whiting; P H Hutson; K C Fone; S M Biello; J J Kulagowski; G McAllister
Journal:  Neuropharmacology       Date:  2005-03       Impact factor: 5.250

9.  Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine.

Authors:  V P Bakshi; M A Geyer
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

Review 10.  Role of serotonin in the action of atypical antipsychotic drugs.

Authors:  H Y Meltzer
Journal:  Clin Neurosci       Date:  1995
View more
  20 in total

Review 1.  Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.

Authors:  Marcello Leopoldo; Enza Lacivita; Francesco Berardi; Roberto Perrone; Peter B Hedlund
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

Review 2.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

Review 3.  Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives.

Authors:  Anne Matthys; Guy Haegeman; Kathleen Van Craenenbroeck; Peter Vanhoenacker
Journal:  Mol Neurobiol       Date:  2011-03-22       Impact factor: 5.590

4.  Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment.

Authors:  Nurith Amitai; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2008-09-08       Impact factor: 3.533

5.  The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice.

Authors:  Wei-Li Chang; Mark A Geyer; Mahalah R Buell; Martin Weber; Neal R Swerdlow
Journal:  Behav Pharmacol       Date:  2010-03       Impact factor: 2.293

6.  Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague-Dawley rats.

Authors:  Wei-li Chang; Michelle R Breier; Alex Yang; Neal R Swerdlow
Journal:  Pharmacol Biochem Behav       Date:  2011-06-12       Impact factor: 3.533

Review 7.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

Review 8.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

9.  Serotonin 5-HT(7) receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: therapeutic implications for psychiatric disorders.

Authors:  Minako Tajiri; Atsuko Hayata-Takano; Kaoru Seiriki; Katsuya Ogata; Keisuke Hazama; Norihito Shintani; Akemichi Baba; Hitoshi Hashimoto
Journal:  J Mol Neurosci       Date:  2012-07-29       Impact factor: 3.444

10.  Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat.

Authors:  Samantha L McLean; Marie L Woolley; Dave Thomas; Joanna C Neill
Journal:  Psychopharmacology (Berl)       Date:  2009-07-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.